Product & Industry News
Drug Discovery World
Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

30 July 2020
Image: Ani Kolleshi

The US Department of Defence (DOD) has awarded Evotec's Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19

Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good Manufacturing Practice (cGMP) clinical supplies of two monoclonal antibodies directed against SARS-CoV-2 antigens. The mAbs will be tested in early-stage clinical trials and ultimately, used for intervention and/or prevention of SARS-CoV-2 infections. Just–Evotec Biologics will use its experience in process development and clinical manufacturing to enable the rapid realisation of these potentially critical protein therapeutic treatments against SARS CoV 2 infections.

Dr James Thomas, Executive Vice President Global Head Biotherapeutics at Just–Evotec Biologics commented: “It is an honour to be working with the Department of Defence on this important and time-critical programme. The response to COVID-19 requires the application of rapid, flexible, scalable and robust development and manufacturing technologies. Our company and our platform were designed for the type of rapid response required to develop safe and efficacious products needed for the fight against COVID-19 and future pandemics.”

More on this subject...
The apocalyptic horsemen of the pharma industry cartoon illustration

The Apocalyptic Horsemen of Drug Discovery and Development READ MORE

A roadmap for achieving self-sustainability of academic high throughput screening core facilities READ MORE

Editing the Human Genome: Role in Functional Genomics and Translational Medicine READ MORE

New Tools Increase Accessibility to High Content Screening Assays READ MORE

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery Main Image

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery READ MORE

In Vivo Imaging In Drug Development: Gamma Scintigraphy READ MORE

Innovate while derisking drug development - yes we can!

Innovate While Derisking Drug Development: Yes We Can! READ MORE

Stem cells, cell-based assays and the world of small molecules

Stem Cells: Cell-Based Assays and the World of Small Molecules READ MORE

Pharmaceutical and biomedical research likely to use 1 billion dollars worth of microfluidics devices by 2016

Pharmaceutical & biomedical research likely to use $1 billion worth of microfluidics devices by 2016 READ MORE

Asian innovation

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry READ MORE